India's dairy sector pushes for safeguards in US trade talks
MUMBAI, May 26 (Reuters) - India, the world's largest milk producer, must protect millions of small dairy farmers in its trade talks with the United States to avoid market disruption from any surge in U.S. imports, industry officials said.
India is negotiating a comprehensive bilateral trade agreement with the United States after Washington imposed reciprocal tariffs including a 26% duty on Indian goods, later paused for 90 days.
The United States, whose dairy exports reached $8.22 billion last year, is pushing for greater access to India's dairy market, which remains shielded by high import duties and non-tariff barriers.
"It is necessary that we do not give them very cheap access to our markets," said Jayen Mehta, managing director of the Gujarat Co-operative Milk Marketing Federation Ltd (GCMMF), which owns Amul, a household name and the country's largest dairy brand.
"They are intended to dump their surplus in our country, which we cannot afford," Mehta said.
The average herd size in India is only two to three animals per farmer, compared to hundreds in the United States - a difference that puts small Indian farmers at a disadvantage, industry officials say.
India's dairy sector feeds more than 1.4 billion people and provides livelihoods to 80 million farmers, making it critical that trade negotiations do not harm milk producers, most of whom are rural poor, Mehta said.
India accounts for nearly a quarter of global milk production, with output reaching 239 million metric tons, more than double U.S. output of around 103 million tons. The Indian dairy industry is valued at $16.8 billion.
New Delhi has previously excluded the dairy sector from bilateral trade agreements and will continue to protect it, as the government recognises its role in supporting small farmers, said R.S. Sodhi, president of the Indian Dairy Association.
The country's dairy industry should also be protected due to cultural and dietary considerations, as cattle in the United States are often fed feed containing animal by-products, which does not align with Indian consumer preferences, Sodhi said.
A senior official at the federal trade ministry said India is resisting pressure from the United States to open its dairy sector in the current bilateral trade talks.
India will not surrender under any circumstances, and the dairy sector will continue to enjoy protection, said the official, who did not wish to be named since the deliberations were not public.
Dairy farmers say they need government protection.
"The government needs to make sure we're not hit by cheap imports from other countries," said farmer Mahesh Sakunde from the western state of Maharashtra. "If that happens, the whole industry will suffer, and so will farmers like us."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 hours ago
- The Independent
India opens world's highest railway arch bridge built with 28,000 tonnes of steel
Indian Prime Minister Narendra Modi inaugurated the Chenab Railway Bridge, the World 's tallest railway arch bridge at 359m above the Chenab River, 35m taller than the Eiffel Tower, connecting Kashmir to the rest of India via rail. The 1,315m bridge, part of the Udhampur-Srinagar-Baramulla Rail Link (USBRL) project, was built with over 28,000 tonnes of Steel, designed to last 120 years, and can withstand high winds (up to 266kmph) and seismic activity (up to magnitude 8). Engineering challenges included stabilising slopes in the fractured Himalayan geology, with G Madhavi Latha from the Indian Institute of Science advising on slope stabilisation and foundation design, requiring real-time construction plan modifications based on geological data. Construction involved building 26km of new roads to transport heavy machinery to the remote site, with the USBRL project costing Rs437.8bn (£3.7bn) and the Chenab Bridge alone costing approximately Rs14.86bn (£128m). The Chenab Bridge, designed with contributions from Indian and international firms, including WSP Finland and Leonhardt Andrä und Partner, aims to significantly reduce travel time between Katra and Srinagar to three hours via the Vande Bharat Express.
Auto Blog
4 hours ago
- Auto Blog
Japan's Sub-$10K EV Seats One But Turns Heads
Tiny cars have never not been cool, but the one-seater MiBot from Japan-based KG Motors is making a real impression on the car-buying public A small 'mobility robot' could change the way Japan gets around Pricing is one of many reasons EV market penetration worldwide is slow. But in Japan, a country historically not as dependent on the automobile as places like the United States, the electric vehicle segment is growing at a particularly modest pace. With just 3.5 percent of the market share in Japan as of 2023, compared to a global percentage nearer to 20 percent, EVs are far from the popular choice. But a company called KG Motors, based near Hiroshima, is hoping that will change with their idea of the perfect city car: the MiBot. The MiBot is small and perfect for getting downtown KG Motors MiBot — Source: KG Motors Really, there's only one way to say it: the KG Motors MiBot is tiny. The single seater measures 98 inches long, 44 inches wide, and stands just 57 inches tall, making it more or less the size of a golf cart. Under the admittedly adorable exterior beats an electric heart that offers up to 62 miles of range at up to 37 mph. A 7.68 kWh LFP battery pack charges in around five hours on a 100-volt outlet, which is Japan's standard. Despite a spartan interior — KG Motors proudly touts 'doors and air conditioners are standard' — the company says it's looking into 'autonomous driving functions.' Reservations opened up last August, and KG Motors has already secured over 2,000 pre-orders. Now, small cars and electrification aren't a new pairing in Japan. The Nissan Sakura, arguably the most popular EV in Japan, is in fact a kei car. But the KG Motors MiBot differs in a few key ways. Funny enough, the most important difference is that it's smaller, conforming to regulations in Japan defining a 'microcar.' That's distinct from even the small kei car. Microcars benefit from lower insurance rates, no required inspections, and freedom from some other local regulations. The second most important part is pricing. Priced at roughly the equivalent of $7,650, the MiBot is less than half the price of the Sakura. KG Motors MiBot — Source: KG Motors MiBot, like Slate Auto, is filling a gap that legacy automakers seem to be content to ignore We won't be so bold as to suggest the MiBot would be a pragmatic choice, or at all successful, Stateside. We also recognize that there isn't anything quite analogous to a microcar that exists in the US. However, with KG Motors seeing a positive response in a country that otherwise eschews electrification in favor of gas — or nothing at all — it seems that pricing is perhaps a bigger factor than legacy automakers realize. Slate Auto is seeing a hugely successful reservation period, and the two share a common approach: few frills, and a price that undercuts everyone else, especially legacy automakers. Autoblog Newsletter Autoblog brings you car news; expert reviews and exciting pictures and video. Research and compare vehicles, too. Sign up or sign in with Google Facebook Microsoft Apple By signing up I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . You may unsubscribe from email communication at anytime. KG Motors MiBot — Source: KG Motors Final thoughts In an interview with Bloomberg, KG Motors said the 'first batch' of MiBots will allow the company to 'break even,' financially speaking. Following reservation fulfillments, the MiBot makers will start churning these little guys out at a rate of 10,000 units per year. It's important to remember that Toyota, the world's largest automaker, sold around 2,000 EVs total in Japan last year. Price isn't everything, but we have a feeling keeping it low is a big boost for little cars like the MiBot in Japan, and value-packed offerings from companies like Slate in the US. About the Author Steven Paul View Profile
Reuters
5 hours ago
- Reuters
Otsuka's kidney disease therapy trial results heat up battle with rival Vera
June 6 (Reuters) - Otsuka's (4578.T), opens new tab experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new treatment with rival Vera Therapeutics (VERA.O), opens new tab. The Japan-based company said on Friday its therapy, sibeprenlimab, cut proteinuria levels by 51.2% in patients with Immunoglobulin A Nephropathy, also known as Berger's disease, at nine months in a late-stage trial. The data comes just days after Vera said its drug, atacicept, reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo, meeting the main goal of a 428-patient late-stage study. Shares of the U.S.-based drug developer slid 31% to $20.89. Analysts, however, said that though data from Otsuka's sibeprenlimab might look superior, it was unlikely that doctors would interpret it that way. The difference between the two datasets is not too clinically diverse to affect demand for Vera's drug, said Jefferies analyst Farzin Haque. Berger's disease causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure. Analysts have estimated the U.S. market for its treatments could be worth as much as $10 billion. Otsuka has already applied for the FDA's accelerated approval for its therapy to treat the disease. However, its sales would largely depend on whether the treatment can improve kidney function, analysts said. Even if the drug gains accelerated approval, Otsuka said it plans to study whether it can preserve the organ's ability to filter toxins from blood, measured as the glomerular filtration rate (eGFR). "The magnitude of the protein reduction should translate into eGFR preservation down the line, because ultimately that's what patients are going to be asking for," Dana Rizk, the trial's investigator and a professor of medicine at the University of Alabama in Birmingham, told Reuters. The study is expected to be completed in early 2026.
